View Document Preview and Link Document Date: 2011-08-15 11:58:24 Open Document File Size: 46,45 KB Share Result on Facebook
City NEW ORLEANS / Seattle / / Company De Novo Ventures / HemaQuest Pharmaceuticals / Lilly Ventures / Forward Ventures / / Continent Europe / / Country United States / / Event Funding / FDA Phase / / Facility University School / / IndustryTerm biopharmaceutical / / MedicalCondition hemoglobin disorders / strokes / cancer / disease / Beta thalassemias / chronic damage / acute chest syndrome / severe / transfusion-dependent anemia / genetic disorder / viral-related hematologic malignancies / both sickle cell disease / pain / serious anemias / serious and life-threatening diseases / lung injury / diseases / Sickle Cell Disease / beta thalassemia / hemoglobin diseases / Infections / ABOUT SICKLE CELL DISEASE AND BETA THALASSEMIA Sickle cell disease / / MedicalTreatment red blood cell transfusions / chemotherapy / / Organization Boston University School of Medicine / American Society of Hematology in New Orleans / / Person Susan Perrine / Ronald Berenson / / Position Chief Scientific Officer and Vice President / Clinical Affairs / / President and CEO / Chief Scientific Officer and Vice President / Clinical Affairs / / Product hydroxyurea / United States / / ProvinceOrState Massachusetts / / Technology SCFAD technologies / chemotherapy / transplantation / / URL www.HemaQuest.com / / SocialTag 
HemaQuest Pharmaceuticals - Promising Results in Sickle Cell and Beta Thalassemia Drug _12-08-2009_